chartexchange

TriSalus Life Sciences Reports Third Quarter 2026 Results

Business Wire | Nov 10, 2026 8:05 AM EST

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended September 30, 2026, and provided an operational update. “The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-o

Read original article